Crescent Biopharma (CBIO) Income towards Parent Company (2013 - 2026)

Crescent Biopharma (CBIO) has reported Income towards Parent Company for 14 consecutive years, with -$24.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Income towards Parent Company fell 13.98% year-over-year to -$24.8 million; the TTM figure through Jun 2026 stood at -$230.9 million (down 345.61% YoY), while the FY2025 annual figure was -$153.9 million, down 306.18% from the prior year.
• Income towards Parent Company rose to -$24.8 million in Q2 2026 per CBIO's latest filing, from -$76.3 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$2.3 million in Q1 2025 and bottomed at -$90.4 million in Q4 2025.
• Historically, Income towards Parent Company has averaged -$21.5 million across 5 years, with a median of -$10.5 million in 2023.
• Annual changes were most pronounced in 2025 — Income towards Parent Company surged 78.17% — and 2026, when it sank 3154.72%.
• Crescent Biopharma's Income towards Parent Company stood at -$10.2 million in 2022, then grew by 11.38% to -$9.1 million in 2023, then sank by 96.8% to -$17.9 million in 2024, then sank by 405.94% to -$90.4 million in 2025, then soared by 72.52% to -$24.8 million in 2026.
• Business Quant data shows CBIO's Income towards Parent Company at -$24.8 million in Q2 2026, -$76.3 million in Q1 2026, and -$90.4 million in Q4 2025.